RCT of omega-3 fatty acids as treatment of subthreshold symptoms in young people at ultra-high risk for

Funded Activity Summary

Omega-3 fats are a type of polyunsaturated fat which has long been thought to be beneficial for health. The body cannot make its own omega-3 fats - they must be taken in through the diet, or in supplement form. Large population-based studies have suggested that a diet rich in omega-3 fats can reduce the risk of cardiovascular disease, lower blood pressure, cut the risk of cancers such as prostate and skin. The fats have also been touted as a treatment for arthritis, asthma, and inflamed bowels. A lack of omega-3s during foetal development can hinder brain and eye development. Other work has suggested that a diet rich in omega-3 may help improve mental health. Studies revealed beneficial effects in a broad range of mental health problems including violent and aggressive behaviour in teenagers, major depression, bipolar affective disorder, borderline personality disorder, and schizophrenia. Evidence that omega-3 fatty acids may reduce symptoms in schizophrenia and other major psychiatric disorders make omega-3 fatty acids an optimal candidate for further evaluation of its therapeutic efficacy, in particular in young people in early illness stages of psychosis where specific intervention is controversial due to potential risks and medication side-effects. The proposed 12-week intervention study aims to establish a new treatment strategy alternative to antipsychotic medication in the young people with subthreshold symptoms at high risk for psychosis. Omega-3 fatty acids have no clinically relevant side effects which often accompany therapy with antipsychotics (such as diabetes and weight gain). A widely available, easy applicable, biological treatment without clinically relevant side effects could help to improve compliance and outcome in psychosis. Schizophrenia is often prolonged and results in a considerable economic burden. Early treatment has the potential to offset future costs to both mental health providers and the recipients of these services.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2011

Funding Scheme: NHMRC Strategic Awards

Funding Amount: $280,102.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Paediatrics not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Essential fatty acids | Fatty acid metabolism | Prevention | Randomised controlled trial | Schizophrenia

Related Links